Sykes M
Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02129, USA.
J Intern Med. 2007 Sep;262(3):288-310. doi: 10.1111/j.1365-2796.2007.01855.x.
The achievement of immune tolerance, a state of specific unresponsiveness to the donor graft, has the potential to overcome the current major limitations to progress in organ transplantation, namely late graft loss, organ shortage and the toxicities of chronic nonspecific immumnosuppressive therapy. Advances in our understanding of immunological processes, mechanisms of rejection and tolerance have led to encouraging developments in animal models, which are just beginning to be translated into clinical pilot studies. These advances are reviewed here and the appropriate timing for clinical trials is discussed.
实现免疫耐受,即对供体移植物产生特异性无反应状态,有可能克服当前器官移植进展中的主要限制,即晚期移植物丢失、器官短缺以及慢性非特异性免疫抑制治疗的毒性。我们对免疫过程、排斥和耐受机制的理解取得了进展,这在动物模型中带来了令人鼓舞的发展,而这些发展刚刚开始转化为临床试点研究。本文对这些进展进行了综述,并讨论了临床试验的适当时机。